Celltrion’s Remsima receives ‘approval recommendation’ for all indications

On the 9^th of February(local time), Celltrion announced the first biosimilar antibody, ‘Remsima,’ received ‘approval recommendation’ for all the indications applied from the U.S. Food and Drug Administration(FDA) Arthritis Advisory Committee, like its original drug.

At the meeting held at the FDA’s White Oak Campus in Maryland, the Committee took a general vote after the Celltrion and FDA’s an...